Coated Balloon Versus Coated Stent for Heart Attack in Adults
Compares a drug-coated balloon with a drug-coated stent in adults with STEMI heart attack.
Plain-language title generated from the registry record
Registry title: Drug-Coated Balloon Versus Drug-Eluting Stent in Patient With ST-Segment Elevation Myocardial Infarction
Key facts
- Where
- Hangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having a heart attack with ST-segment elevation who need emergency PCI. It compares a drug-coated balloon with a drug-eluting stent.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute ST-segment elevation heart attack, with symptoms for less than 48 hours, needing emergency PCI. The lesion must be 40mm or shorter, with a vessel diameter of 2mm to 4mm. After clot removal and pre-dilation, the narrowing must be 50% or less.
- Earlier treatment
- No earlier coronary artery bypass surgery.
Main reasons for not taking part
- Allergy or contraindication to the listed blood-thinning drugs or contrast dye
- Active bleeding, or serious bleeding or a clotting disorder in the past 3 months
- Pregnant, or planning to become pregnant during the study
- Left main artery narrowing of 50% or more
- Cardiogenic shock, or on a breathing tube or ventilator
Read by machine on 12 November 2026.
Where in China
- Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHangzhou, ChinaContact: Chi LiuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT06742125
- Record updated
- 28 September 2026
- Original description
Acute ST-segment elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate intervention. The incidence of premature coronary artery disease (PCAD) is rising rapidly in China; its long-term prognosis remains poor and it frequently progresses to acute myocardial infarction, necessitating high-risk therapies such as primary percutaneous coronary intervention (PCI) or coronary artery bypass grafting, thereby imposing enormous economic and psychological burdens on patients and their families. Moreover, the cumulative 6-year rate of death or myocardial infarction after implantation of the latest-generation drug-eluting stents still reaches 15%, and management of stent failure is extremely challenging. Drug-coated balloon (DCB) angioplasty-representing the "leave-nothing-behind" paradigm-is a highly promising option in young subjects. Accumulating clinical evidence demonstrates that DCB provides favorable efficacy across a broad spectrum of lesions, including small-vessel and large-vessel de novo disease, bifurcation lesions, and in-stent restenosis. Nevertheless, high-quality data on the impact of DCB angioplasty in de novo large-vessel disease and in the setting of acute STEMI are still lacking.Read full original descriptionShow less
Drug-Coated Balloon Versus Drug-Eluting Stent in Patient With ST-Segment Elevation Myocardial Infarction
Acute ST-segment elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate intervention. The incidence of premature coronary artery disease (PCAD) is rising rapidly in China; its long-term prognosis remains poor and it frequently progresses to acute myocardial infarction, necessitating high-risk therapies such as primary percutaneous coronary intervention (PCI) or coronary artery bypass grafting, thereby imposing enormous economic and psychological burdens on patients and their families. Moreover, the cumulative 6-year rate of death or myocardial infarction after implantation of the latest-generation drug-eluting stents still reaches 15%, and management of stent failure is extremely challenging. Drug-coated balloon (DCB) angioplasty-representing the "leave-nothing-behind" paradigm-is a highly promising option in young subjects. Accumulating clinical evidence demonstrates that DCB provides favorable efficacy across a broad spectrum of lesions, including small-vessel and large-vessel de novo disease, bifurcation lesions, and in-stent restenosis. Nevertheless, high-quality data on the impact of DCB angioplasty in de novo large-vessel disease and in the setting of acute STEMI are still lacking.
Inclusion: . Age of Patients ≥18 years old; Acute myocardial infarction patients with onset symptoms<48 hours require emergency PCI; . Diagnosis: Chest pain and other ischemic symptoms accompanied by ST segment elevation in at least two adjacent leads on electrocardiogram (① V2 or V3 lead: male<40 years ≥ 0.25mV, ≥ 40 years ≥ 0.2mV; Female ≥1.5mV；② Other leads ≥ 1mV), or new left bundle branch block occurs; Criminal blood vessels with clear requirements for emergency PCI; Coronary artery in situ lesions, with a visual reference lumen diameter of ≥ 2mm and ≤ 4mm; Lesion's length<40mm；; After thrombus aspiration and pre dilation, the lesion stenosis is ≤ 50% and there is no C-type or above dissection; He/she or his/her legal representative voluntarily participates in this study and signs an informed consent form.
Exclusion: History of significant gastrointestinal or urogenital bleeding or bleeding tendency within 3 months prior to surgery, known coagulation disorders (including heparin induced thrombocytopenia); The patient has allergies or contraindications to the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Cilostazol, Indobufen, Contrast Medias (Patients with clear contrast agent allergies such as rash but can be controlled with effective drugs such as glucocorticoids and diphenhydramine in advance can be selected); The patient has active pathological bleeding; History of coronary artery bypass grafting in the past; Patients who are pregnant or have the intention to become pregnant during the period of research; Non cardiogenic combined lesions show an expected life expectancy of less than one year; Left main trunk's stenosis ≥ 50%; Intubation or mechanical ventilation status; . Cardiogenic Shock; . Without signature on informed consent.